Navalign, LLC Allogene Therapeutics, Inc. Transaction History
Navalign, LLC
- $336 Million
- Q4 2024
A detailed history of Navalign, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Navalign, LLC holds 59,865 shares of ALLO stock, worth $101,171. This represents 0.04% of its overall portfolio holdings.
Number of Shares
59,865
Previous 75,365
20.57%
Holding current value
$101,171
Previous $211,000
39.81%
% of portfolio
0.04%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$31.6 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$27.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$18.4 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$13.5 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$12.3 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $243M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...